MED6 antibody - middle region (ARP34219_P050)
- Known as:
- MED6 (anti-) - middle region (ARP34219_P050)
- Catalog number:
- arp34219_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- MED6 antibody - middle region (ARP34219_P050)
Related genes to: MED6 antibody - middle region (ARP34219_P050)
- Gene:
- MED6 NIH gene
- Name:
- mediator complex subunit 6
- Previous symbol:
- -
- Synonyms:
- NY-REN-28
- Chromosome:
- 14q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-12-09
- Date modifiied:
- 2016-10-05
Related products to: MED6 antibody - middle region (ARP34219_P050)
Related articles to: MED6 antibody - middle region (ARP34219_P050)
- Pathogens disrupt transcriptional hubs to subvert host immunity, yet the spatiotemporal mechanisms remain enigmatic. Here, we report a pathogen effector interferes with the core eukaryotic transcriptional machinery by acting as a functional mimic of host repressors, deploying this suppression in synchrony with the plant immune rhythm. We discover the Phytophthora sojae nuclear effector directly targets the host Mediator complex. Crucially, PsAvh109 emulates the host repressor TOPLESS (TPL), competitively occupying the Mediator subunit MED21 and locks the MED21-MED6 interaction interface, repressing salicylic acid (SA)-responsive defense genes. Strikingly, PsAvh109 expression is induced by host-derived SA, the very signal displaces TPL from MED21 to activate immunity. This enables the pathogen to release the essential effector PsAvh109 precisely when the host initiates defense, perpetuating transcriptional repression during a critical vulnerability window. Our findings reveal a previously unrecognized strategy where pathogens exploit host signaling dynamics to release effectors that enforce sustained repression of defense programs. - Source: PubMed
Publication date: 2026/04/15
Tan XinweiSun YujingQi ZhaomeiMiao YonghuiLiu ZhenWan YimanHou XiaoyuanLi HengjingLi WenxiuChen YuanXu QianWang Qunqing - Malaria remains a global health crisis, exacerbated by the rise of drug-resistant strains of Plasmodium species to clinically used drugs, as well as newly developed therapeutic agents. Historically, natural-product-derived drugs such as quinine and artemisinin have been the cornerstones of malaria treatment, distinguished by their ability to attack the parasite on multiple fronts simultaneously. This review explores the paradigm of single drugs with multiple targets, a polypharmacology strategy designed to achieve combination-therapylike efficacy within a single compound. We discuss how natural products leverage multitarget mechanisms of action, reducing the likelihood of resistance, and the opportunities and challenges in developing next-generation antimalarials. Understanding and harnessing polypharmacology in antimalarial drug design could prolong therapeutic durability and reinvigorate our arsenal against malaria. - Source: PubMed
Publication date: 2026/03/16
Milić MiraObi PriscaVanderwal Christopher DBen Mamoun ChoukriLe Roch Karine G - The formation of the bilaterian anterior-posterior axis relies on deeply conserved patterning systems, yet how these evolved remains incompletely understood. As sister to or within Gnathifera, chaetognaths provide an informative phylogenetic context for investigating anterior-posterior patterning, yet their developmental genetics remain poorly studied. Here, we examine anterior patterning (otx, nk2.1, six3/6) and Hox gene expression in the chaetognath Spadella cephaloptera. Anterior patterning genes are expressed in cerebral neural regions as in other bilaterians. In contrast, Hox genes, including the previously undescribed med6, postC, and postD, show staggered expression along the nervous system, resembling the proposed ancestral bilaterian condition. Posterior Hox genes are also expressed in the postanal tail, a trait only present in chaetognaths and chordates, suggesting a link between Hox expansion and the independent emergence of this structure. Our results indicate that chaetognaths retain ancestral bilaterian features and provide insights into Hox-driven lineage-specific innovations within Spiralia. - Source: PubMed
Publication date: 2025/12/26
Ordoñez June FWollesen Tim - Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Recent studies have highlighted the importance of Mediator complex subunits in cancer, but their specific roles in LUAD are still unclear. The CRISPR-Cas9 loss-of-function data was used to assess gene dependency in cell growth. RNA-seq data were analyzed to evaluate the prognostic value of Mediator subunits and explore their downstream pathways. Single-cell sequencing data were utilized to examine the tumor microenvironment in LUAD. A drug sensitivity analysis was performed to identify potential therapeutic options. Mediator complex subunit 6 (MED6) was found to influence tumor cell growth in LUAD. Additionally, MED6 expression levels were associated with patient prognosis. MED6-positive tumor cells showed more active interactions with other cells in the LUAD microenvironment, promoting tumor progression. Based on MED6 expression, drugs such as paclitaxel, afatinib, and brivanib were identified as potential treatments. This study revealed the role of MED6 in LUAD and its potential as a biomarker. Our findings suggest that MED6 has an effect on LUAD progression and provide valuable insights for patient stratification and personalized treatment strategies. - Source: PubMed
Publication date: 2025/04/13
Yang ChangqingCheng DingWang ShuoWang BaichuanLi YingxiWang GuixinWang XingkaiShi CangchangTian YaoZhu KeyunFeng Jing - - Source: PubMed
Publication date: 2025/03/24
Khan NimraNawaz AyeshaShabbir Aimun